Til Nasdaq Copenhagen A/S Humlebæk, den 26. marts 2026 Selskabsmeddelelse nr. 10/2026 Indkaldelse til ordinær generalforsamling i SKAKO A/S SKAKO A/S ("SKAKO") indkalder til ordinær generalforsamling i selskabet til afholdelse fredag den 17. april 2026 kl. 09.00 på Restaurant Sletten, Gl. Strandvej 137, 3050 Humlebæk. Det bemærkes, at der hverken vil være forplejning før, under eller efter generalforsamlingen. Indkaldelsen er sket jf. selskabets vedtægter §7. Indkaldelsen, der indeholder dagsordenen og ...

Core Point - The document provides a monthly disclosure of the total number of shares and voting rights for Ipsos as of February 28, 2026, indicating a total of 43,203,225 shares and 49,276,265 theoretical voting rights, with 49,093,732 exercisable voting rights [1]. Group 1 - The total number of shares as of February 28, 2026, is reported to be 43,203,225 [1]. - The theoretical voting rights associated with these shares amount to 49,276,265 [1]. - The number of exercisable voting rights is noted as 49,093,732 [1]. Group 2 - The document clarifies that the theoretical voting rights include shares with suspended voting rights, in accordance with Article 223-11 of the AMF general regulation [1]. - Additional information regarding the voting rights can be found in the "Regulated Information" section of the Ipsos website [2].

Core Viewpoint - Flow Traders is preparing to release its 1Q 2026 results, highlighting increased market trading volumes and volatility due to geopolitical tensions, particularly in the Middle East, which have positively impacted the company's performance [2][3][11]. Market Environment - Market trading volumes and volatility across most asset classes and regions were higher year-on-year and quarter-on-quarter, influenced by geopolitical tensions [3]. - In Equity, trading volumes increased across most regions, with the exception of Japan, which saw a minor decline quarter-on-quarter [3][4]. - Fixed Income trading volumes also increased, with low volatility at the start of the year but a significant rise towards the end of 1Q 2026 [3][6]. - Digital Assets experienced a year-on-year increase in trading volumes but a quarter-on-quarter decrease, with volatility showing mixed trends [3][7]. Asset Class Analysis - **Equity**: European exchanges saw increased trading volumes compared to the previous year and the last quarter, while US markets also reported similar trends. Volatility increased significantly in March due to geopolitical factors [4][5]. - **Fixed Income**: Trading volumes rose across most products, with a notable increase in volatility in March [6]. - **Digital Assets**: Trading volumes decreased both year-on-year and quarter-on-quarter, while activity in tokenized real-world assets is on the rise [7]. ETP Market Volumes - On and Off Exchange Value Traded increased significantly: 27% in EMEA, 70% in the Americas, 100% in APAC, and 73% globally year-on-year. Average volatility, as indicated by the VIX, rose by 5% year-on-year [8]. - Compared to the previous quarter, On and Off Exchange Value Traded was up 18% in EMEA, 7% in the Americas, 10% in APAC, and 8% globally [9]. Impact on Flow Traders - The increased market trading volumes and volatility in March positively impacted Flow Traders' performance across all regions compared to the fourth quarter. Fixed Operating Expenses remained within the previously guided range [11].

Core Insights - Tevogen is in advanced evaluation of a niche contract research organization (CRO) that operates in over 20 countries, which is expected to enhance its capabilities in oncology, rare diseases, and medical devices [1][2] - The potential transaction could add more than $20 million in annual revenue and support double-digit growth starting next year, marking a significant step towards a diversified healthcare enterprise [2][4] - The combination of Tevogen and the target CRO is anticipated to leverage complementary expertise and global reach, focusing on high-quality solutions in specialized therapeutic areas [3] Financial Impact - The transaction is projected to contribute over $20 million in annual revenue, with the potential for Tevogen to generate closer to $100 million in annual revenue through additional acquisition opportunities [2][4] - The company aims to build a scalable, cash-flow-oriented operating model, which is essential for its long-term growth strategy [3] Strategic Initiatives - Tevogen is exploring various strategic initiatives, including domestic generics, biosimilars, medical devices, and innovative insurance solutions, to broaden patient access and advance sustainable innovation [8] - The company is focused on delivering affordable, next-generation healthcare solutions while maintaining fiscal sovereignty [4][5] Technological Advancements - Tevogen is leveraging artificial intelligence and precision T cell therapy platforms to support the development of advanced therapies across multiple therapeutic areas [5][6] - The Tevogen.AI platform aims to transform drug development by optimizing clinical trial design and reducing failure rates through predictive technologies [7]

Core Viewpoint - Valneva SE is actively participating in the 26th World Vaccine Congress, showcasing its advancements in vaccine development, particularly for chikungunya, and engaging with partners in the industry [1][5]. Group 1: Company Participation and Events - Valneva will be represented by its CEO Thomas Lingelbach and senior executives at the World Vaccine Congress from March 31 to April 2, 2026 [1]. - On April 1, 2026, Susanne Eder-Lingelbach will present updates on chikungunya vaccine development, focusing on Phase IV and real-world evidence studies [2]. - Valneva's Chief Medical Officer, Dr. Juan Carlos Jaramillo, will participate in a panel discussion on chikungunya and mosquito-borne vaccines on the same day [4]. Group 2: Chikungunya Vaccine Campaign - Valneva and Instituto Butantan have launched a pilot vaccination campaign for the chikungunya vaccine IXCHIQ® in Brazil, with over 12,000 individuals vaccinated to assess the vaccine's effectiveness and safety in real-world conditions [3]. Group 3: Industry Context - Chikungunya virus (CHIKV) is a significant public health concern, with over 3.7 million cases reported in the Americas between 2013 and 2023, and its economic impact is expected to grow due to climate change [6]. - The World Health Organization (WHO) has identified chikungunya as a major public health problem, emphasizing the need for effective vaccines [6]. Group 4: Company Overview - Valneva is a specialty vaccine company focused on developing, manufacturing, and commercializing vaccines for infectious diseases, addressing unmet medical needs [7]. - The company has a strong track record in advancing vaccines from early R&D to approvals and currently markets three proprietary travel vaccines [8]. - Revenues from its commercial business support the advancement of its vaccine pipeline, which includes candidates for Lyme disease and Shigella, among others [9].

Core Insights - Transgene announced a 30-minute oral presentation on TG4050, an Individualized Neoantigen Therapeutic Vaccine, at the World Vaccine Congress from March 31 to April 2, 2026, in Washington, D.C. [1] - The presentation will focus on findings from the Phase 1 part of the ongoing Phase 1/2 trial in head and neck cancer, discussing the potential of individualized neoantigen vaccines to transform early-stage cancer treatment [2][3] Company Overview - Transgene is a biotechnology company specializing in the design and development of virus-based immunotherapies for cancer treatment, with TG4050 being its lead asset [5] - The company utilizes the myvac® platform to create individualized therapeutic vaccines tailored to each patient's tumor characteristics, supported by AI technology from its partner NEC [7] Clinical Trial Insights - In the Phase 1 trial, patients with resected head and neck cancer treated with TG4050 developed new immune responses targeting specific neoantigens, with all treated patients remaining tumor-free two years post-treatment [3] - Transgene aims to continue generating clinical data for head and neck cancer and other indications to prevent cancer relapse in at-risk patients [4]

Core Insights - DEME released its Annual Report 2025, highlighting the group's strategy, operational performance, ESG progress, and financial results [1] - The year 2025 marked another record year for DEME, achieving all-time high profitability [1] - 2026 is expected to be a milestone year as DEME celebrates its 150th anniversary [1] Financial Performance - The report indicates that DEME built on the strong momentum of previous years, leading to record profitability in 2025 [1] ESG Progress - The Annual Report includes a comprehensive overview of the company's progress in Environmental, Social, and Governance (ESG) initiatives [1]

Core Insights - XA Investments LLC has appointed Lauren Michalak as managing director and head of product development and strategy, focusing on proprietary closed-end funds and interval fund consulting clients [1][2] Group 1: Company Overview - XA Investments LLC is a Chicago-based alternative investment management and consulting firm founded in 2016 by XMS Capital Partners [6] - The firm serves as the investment adviser for two listed closed-end funds and one interval closed-end fund, including the XAI Octagon Floating Rate & Alternative Income Trust, the XAI Madison Equity Premium Income Fund, and the Octagon XAI CLO Income Fund [6] - XA Investments provides investment fund structuring and consulting services, focusing on registered closed-end funds to meet institutional client needs [6] Group 2: Leadership and Experience - Lauren Michalak has two decades of experience in product innovation, strategy, and enterprise execution, having raised over $15 billion in new capital [2][3] - Prior to joining XA Investments, Michalak spent 20 years at Nuveen, where she led product development and strategic initiatives, including managing over $100 billion in assets under management for the Responsible Investing business line [3] - Michalak holds an MBA from The University of Chicago Booth School of Business and a BA in economics and mathematics from Loyola University Chicago, graduating with highest honors [5] Group 3: Strategic Vision - Michalak expressed enthusiasm for XA Investments' partnership model, which focuses on custom product designs and collaboration with clients to create differentiated evergreen fund solutions for private wealth [4]

Acquisition of Own Shares - Sanoma Corporation executed a share buyback on 26 March 2026, acquiring 22,000 shares at an average price of EUR 9.0884 per share, with a total cost of EUR 199,944.80 [1] - The highest and lowest prices per share during the transaction were EUR 9.1100 and EUR 9.0200, respectively [1][2] Shareholding Information - Following the acquisition, Sanoma holds a total of 1,075,392 of its own shares [2] Company Overview - Sanoma is a learning and media company operating across Europe, focusing on providing high-quality educational content and solutions for K12 education [2][4] - The company employs nearly 5,000 professionals and reported net sales of approximately EUR 1.3 billion in 2025, with an adjusted operating profit margin of 14.4% [5] Strategic Focus - Sanoma aims to accelerate growth through value-creating mergers and acquisitions (M&A) while responsibly leveraging AI opportunities [4] - The company is committed to sustainability, aligning its strategy with the UN Sustainable Development Goals and minimizing its environmental footprint [4]

Group 1 - Ferrellgas Partners, L.P. has announced that Raudel Arriaga, Director of Logistics, has been recognized as one of Samsara's 100 Fleet Operators to Watch in 2026, highlighting innovation and safety in the propane industry [1][2] - The company emphasizes the importance of safety, fleet stewardship, and operational discipline, which are integral to its operations and culture [2] - Ferrellgas serves propane customers across all 50 states, the District of Columbia, and Puerto Rico, with its Blue Rhino propane exchange brand available at approximately 65,000 locations nationwide [3] Group 2 - The employee-owners of Ferrellgas indirectly own 1.1 million Class A Units of the partnership through an employee stock ownership plan, reflecting a strong commitment to the company's success [3] - The company filed its Annual Report on Form 10-K for the fiscal year ended July 31, 2025, with the Securities and Exchange Commission on October 15, 2025, providing transparency to investors [3]